Laser Treatment of Bladder Tumors in the Outpatient Department
NCT ID: NCT02659332
Last Updated: 2016-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2015-02-28
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Secondary Objective: To evaluate the patients' symptoms during and after the laser TURBT.
* Tertiary Objective: To evaluate the rate of remnant tumor tissue one month after the laser TURBT.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diode Laser Treatment of Bladder Tumors
NCT02738827
Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors
NCT02886026
Development and Validation of a Simulator-based Test in Transurethral Resection of Bladder Tumors
NCT03863028
Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
NCT05337397
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
NCT06525571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Immediately after the procedure the pain assessed by the VAS score will be recorded and the patients are given a QOL questionnaire (EORTC QLQ-BLS24) and a stamped envelope and are asked to return it one week later. The patients will be telephoned after 5 days to remind on the questionnaire and to ash, whether they has had a urinary infection after the procedure.
One month after the laser TURBT a flexible PPD and SPIES guided cystoscopy is performed in the OPD to evaluate the laser efficacy. To confirm that all tumour tissue has been removed a biopsy will be taken from the previous tumor place. The biopsy will be send to the pathologist according to the normal procedure for biopsies. Visual presentation of the laser treated area will be visualized using PDD and SPIES.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TURBT
Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)
TURBT
Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TURBT
Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tumor \< 1.5 cm
* \< 6 tumors
Exclusion Criteria
* Known hypersensitivity to Hexvix® or porfhyrins
* Use of any anticoagulantia
* Macroscopic hematuria
* Pregnant or breast feeding women
* Expected poor compliance
* Patients \< 18 years
* Patients who do not read or understand Danish
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gregers G Hermann
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gregers G Hermann
MD, DM Sc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregers G Hermann, MD, DMSc
Role: PRINCIPAL_INVESTIGATOR
Bispebjerg and Frederiksberg Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Urology, Bispebjerg and Frederiksberg Hospital
Frederiksberg, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26.
Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005 Jan;95(1):59-63. doi: 10.1111/j.1464-410X.2005.05249.x.
van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26.
James AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol Clin North Am. 2013 May;40(2):261-9. doi: 10.1016/j.ucl.2013.01.004. Epub 2013 Feb 13.
Hofstetter A, Frank F, Keiditsch E, Bowering R. Endoscopic Neodymium-YAG laser application for destroying bladder tumors. Eur Urol. 1981;7(5):278-82. doi: 10.1159/000473240.
Davenport K, Keeley FX Jr, Timoney AG. Audit of safety, efficacy, and cost-effectiveness of local anaesthetic cystodiathermy. Ann R Coll Surg Engl. 2010 Nov;92(8):706-9. doi: 10.1308/003588410X12699663904835. Epub 2010 Jul 2.
Syed HA, Talbot N, Abbas A, MacDonald D, Jones R, Marr TJ, Rukin NJ. Flexible cystoscopy and Holmium:Yttrium aluminum garnet laser ablation for recurrent nonmuscle invasive bladder carcinoma under local anesthesia. J Endourol. 2013 Jul;27(7):886-91. doi: 10.1089/end.2012.0696. Epub 2013 Jun 22.
Wong KA, Zisengwe G, Athanasiou T, O'Brien T, Thomas K. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int. 2013 Sep;112(5):561-7. doi: 10.1111/bju.12216. Epub 2013 Jul 2.
Hermann GG, Mogensen K, Toft BG, Glenthoj A, Pedersen HM. Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol. 2012 Feb;46(1):31-6. doi: 10.3109/00365599.2011.637954. Epub 2011 Dec 12.
Turrentine FE, Wang H, Simpson VB, Jones RS. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006 Dec;203(6):865-77. doi: 10.1016/j.jamcollsurg.2006.08.026.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
URU05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.